Literature DB >> 16397213

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

Fons Elstrodt1, Antoinette Hollestelle, Jord H A Nagel, Michael Gorin, Marijke Wasielewski, Ans van den Ouweland, Sofia D Merajver, Stephen P Ethier, Mieke Schutte.   

Abstract

Germ line mutations of the BRCA1 gene confer a high risk of breast cancer and ovarian cancer to female mutation carriers. The BRCA1 protein is involved in the regulation of DNA repair. How specific tumor-associated mutations affect the molecular function of BRCA1, however, awaits further elucidation. Cell lines that harbor BRCA1 gene mutations are invaluable tools for such functional studies. Up to now, the HCC1937 cell line was the only human breast cancer cell line with an identified BRCA1 mutation. In this study, we identified three other BRCA1 mutants from among 41 human breast cancer cell lines by sequencing of the complete coding sequence of BRCA1. Cell line MDA-MB-436 had the 5396 + 1G>A mutation in the splice donor site of exon 20. Cell line SUM149PT carried the 2288delT mutation and SUM1315MO2 carried the 185delAG mutation. All three mutations were accompanied by loss of the other BRCA1 allele. The 185delAG and 5396 + 1G>A mutations are both classified as pathogenic mutations. In contrast with wild-type cell lines, none of the BRCA1 mutants expressed nuclear BRCA1 proteins as detected with Ab-1 and Ab-2 anti-BRCA1 monoclonal antibodies. These three new human BRCA1 mutant cell lines thus seem to be representative breast cancer models that could aid in further unraveling of the function of BRCA1.

Entities:  

Mesh:

Year:  2006        PMID: 16397213     DOI: 10.1158/0008-5472.CAN-05-2853

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  128 in total

1.  BCL2 suppresses PARP1 function and nonapoptotic cell death.

Authors:  Chaitali Dutta; Tovah Day; Nadja Kopp; Diederik van Bodegom; Matthew S Davids; Jeremy Ryan; Liat Bird; Naveen Kommajosyula; Oliver Weigert; Akinori Yoda; Hua Fung; Jennifer R Brown; Geoffrey I Shapiro; Anthony Letai; David M Weinstock
Journal:  Cancer Res       Date:  2012-06-11       Impact factor: 12.701

2.  Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.

Authors:  Boris Kantor; Matthew Bayer; Hong Ma; Jude Samulski; Chengwen Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

3.  The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.

Authors:  Ameer L Elaimy; John J Amante; Lihua Julie Zhu; Mengdie Wang; Charlotte S Walmsley; Thomas J FitzGerald; Hira Lal Goel; Arthur M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

4.  Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Authors:  Amy Dréan; Chris T Williamson; Rachel Brough; Inger Brandsma; Malini Menon; Asha Konde; Isaac Garcia-Murillas; Helen N Pemberton; Jessica Frankum; Rumana Rafiq; Nicholas Badham; James Campbell; Aditi Gulati; Nicholas C Turner; Stephen J Pettitt; Alan Ashworth; Christopher J Lord
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

5.  Delocalization of gamma-tubulin due to increased solubility in human breast cancer cell lines.

Authors:  Edward H Cho; Rebecca A Whipple; Michael A Matrone; Eric M Balzer; Stuart S Martin
Journal:  Cancer Biol Ther       Date:  2010-01-28       Impact factor: 4.742

6.  Analysis of 41 cancer cell lines reveals excessive allelic loss and novel mutations in the SIRT1 gene.

Authors:  Jeehae Han; Basil P Hubbard; Jaehoon Lee; Cristina Montagna; Han-Woong Lee; David A Sinclair; Yousin Suh
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

7.  BRCA1 pathway function in basal-like breast cancer cells.

Authors:  Sarah J Hill; Allison P Clark; Daniel P Silver; David M Livingston
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

8.  BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Authors:  Rinske Drost; Kiranjit K Dhillon; Hanneke van der Gulden; Ingrid van der Heijden; Inger Brandsma; Cristina Cruz; Dafni Chondronasiou; Marta Castroviejo-Bermejo; Ute Boon; Eva Schut; Eline van der Burg; Ellen Wientjens; Mark Pieterse; Christiaan Klijn; Sjoerd Klarenbeek; Fabricio Loayza-Puch; Ran Elkon; Liesbeth van Deemter; Sven Rottenberg; Marieke van de Ven; Dick H W Dekkers; Jeroen A A Demmers; Dik C van Gent; Reuven Agami; Judith Balmaña; Violeta Serra; Toshiyasu Taniguchi; Peter Bouwman; Jos Jonkers
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

9.  RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

Authors:  Yifan Wang; John J Krais; Andrea J Bernhardy; Emmanuelle Nicolas; Kathy Q Cai; Maria I Harrell; Hyoung H Kim; Erin George; Elizabeth M Swisher; Fiona Simpkins; Neil Johnson
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

Review 10.  BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.

Authors:  John J Krais; Neil Johnson
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.